Koyfin Home > Directory > Health Care > Revance Therapeutics > Cost of Goods Sold

Revance Therapeutics Cost of Goods Sold Chart (RVNC)

Revance Therapeutics annual/quarterly Cost of Goods Sold from 2020 to 2020.
  • Revance Therapeutics Cost of Goods Sold for the quarter ending June 06, 2020 was $0m
  • Revance Therapeutics Cost of Goods Sold for the last 12 months ending June 06, 2020 was $0m
Other Income Statement Metrics:
  • Revance Therapeutics EBITDA for the quarter ending December 12, 2018 was $-38m a 7.02% decrease of -3m year over year
  • Revance Therapeutics Net Income for the quarter ending September 09, 2018 was $-33m a -9.36% increase of 3m year over year
  • Revance Therapeutics Total Revenue for the quarter ending September 09, 2018 was $2m a 98.43% increase of 2m year over year
View Chart On Koyfin

Quarterly RVNC Cost of Goods Sold Data

06/2020$0m

Annual RVNC Cost of Goods Sold Data

2011$0m